Assessing sleep in primary brain tumor patients using smart wearables and patient-reported data: Feasibility and interim analysis of an observational study
Author:
Pascoe Maeve M1ORCID, Wollet Alex R1, De La Cruz Minyety Julianie1, Vera Elizabeth1, Miller Hope1, Celiku Orieta1ORCID, Leeper Heather1, Fernandez Kelly2, Reyes Jennifer1, Young Demarrius1, Acquaye-Mallory Alvina1, Adegbesan Kendra1, Boris Lisa2, Burton Eric1, Chambers Claudia P2, Choi Anna1, Grajkowska Ewa1, Kunst Tricia2, Levine Jason3, Panzer Marissa2, Penas-Prado Marta1, Pillai Valentina2, Polskin Lily2, Wu Jing1ORCID, Gilbert Mark R1ORCID, Mendoza Tito1, King Amanda L1, Shuboni-Mulligan Dorela2, Armstrong Terri S1ORCID
Affiliation:
1. Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland 2. Frederick National Laboratory for Cancer Research, Leidos Biomedical Research , Inc, Frederick, Maryland 3. Center for Cancer Research Office of Information Technology, National Cancer Institute, National Institutes of Health , Bethesda, Maryland
Abstract
Abstract
Background
Sleep–wake disturbances are common and disabling in primary brain tumor (PBT) patients but studies exploring longitudinal data are limited. This study investigates the feasibility and relationship between longitudinal patient-reported outcomes (PROs) and physiologic data collected via smart wearables.
Methods
Fifty-four PBT patients ≥ 18 years wore Fitbit smart-wearable devices for 4 weeks, which captured physiologic sleep measures (eg, total sleep time, wake after sleep onset [WASO]). They completed PROs (sleep hygiene index, PROMIS sleep-related impairment [SRI] and Sleep Disturbance [SD], Morningness-Eveningness Questionnaire [MEQ]) at baseline and 4 weeks. Smart wearable use feasibility (enrollment/attrition, data missingness), clinical characteristics, test consistency, PROs severity, and relationships between PROs and physiologic sleep measures were assessed.
Results
The majority (72%) wore their Fitbit for the entire study duration with 89% missing < 3 days, no participant withdrawals, and 100% PRO completion. PROMIS SRI/SD and MEQ were all consistent/reliable (Cronbach’s alpha 0.74–0.92). Chronotype breakdown showed 39% morning, 56% intermediate, and only 6% evening types. Moderate-severe SD and SRI were reported in 13% and 17% at baseline, and with significant improvement in SD at 4 weeks (P = .014). Fitbit-recorded measures showed a correlation at week 4 between WASO and SD (r = 0.35, P = .009) but not with SRI (r = 0.24, P = .08).
Conclusions
Collecting sleep data with Fitbits is feasible, PROs are consistent/reliable, > 10% of participants had SD and SRI that improved with smart wearable use, and SD was associated with WASO. The skewed chronotype distribution, risk and impact of sleep fragmentation mechanisms warrant further investigation.
Trial Registration
NCT04 669 574
Funder
Intramural Research Program National Institutes of Health National Cancer Institute Natural History Study Intramural Project
Publisher
Oxford University Press (OUP)
Reference44 articles.
1. A case of soft tissue metastasis from glioblastoma and review of the literature;Armstrong;J Neurooncol.,2011 2. Sleep disturbance of adults with a brain tumor and their family caregivers: A systematic review;Jeon;Neuro Oncol,2017 3. Exploring the prevalence and burden of sleep disturbance in primary brain tumor patients;King;Neurooncol. Pract..,2022 4. Association of genetic variants with fatigue in patients with malignant glioma;Armstrong;Neurooncol. Pract..,2018 5. Practical strategies for management of fatigue and sleep disorders in people with brain tumors;Armstrong;Neuro Oncol,2012
|
|